Evolocumab In Advanced Chronic Kidney Disease Trial

Summary

110 individuals with stage 4-5 Chronic Kidney Disease (CKD) will be randomized to 1-year of blinded Evolocumab or placebo. Subjects will undergo evaluation of circulating lipids at baseline and end of study. A substudy including 50 subjects will assess myocardial rest and stress positron emission tomography (PET) at baseline and at 1-year.

Timeline

Start

2021-03-01

Primary completion

2021-10-01

Completion

2021-10-01

Drugs

Indications